Xenon Pharmaceuticals Inc. (NASDAQ:XENE) Q1 2022 Earnings Conference Call May 10, 2022 4:30 PM ET

Company Participants

Sherry Aulin - Chief Financial Officer

Ian Mortimer - President & Chief Executive Officer

Chris Kenney - Chief Medical Officer

Chris Von Seggern - Chief Commercial Officer

Conference Call Participants

Andrew Tsai - Jefferies

Paul Matteis - Stifel

Brian Abrahams - RBC Capital Markets

Yatin Suneja - Guggenheim

David Hoang - SMBC

Laura Chico - Wedbush

Operator

Good day. Thank you for standing by, and welcome to the Xenon Pharmaceuticals Reports First Quarter Results Call 2022. At this time, all participants are in a listen-only mode. After the speakers presentation there will be a question-and-answer session. [Operator Instructions].

I would now like to hand the conference over to your speaker today Ms. Sherry Aulin, Chief Financial Officer of Xenon Pharmaceuticals. The floor is yours.

Sherry Aulin

Thank you. Good afternoon, everyone. Thank you for joining us on our call and webcast to discuss Xenon's first quarter 2022 financial and operating results. Joining me are Ian Mortimer, Xenon’s President and Chief Executive Officer; Dr. Chris Kenney, Xenon’s Chief Medical Officer; and Dr. Chris Von Seggern, Xenon’s Chief Commercial Officer.

Please be advised that during this call, we will make a number of statements that are forward-looking, including statements regarding our and our collaborators' development plans; anticipated regulatory interactions and submissions; anticipated results and real time lines; the potential efficacy, safety profile, addressable market and commercial potential of our proprietary and partnered product candidates; the efficacy of our clinical trial designs and anticipated enrollment; the potential receipt of milestone payments and royalties from our collaborators; our expectation of having sufficient cash to fund operations into at least 2024; and the timing of potential release of future clinical data.

Forward-looking statements are subject to numerous risks and uncertainties, many of which are beyond our control including the risks and uncertainties described from time to time in our SEC filings. Our results may differ materially from those projected on today's call. We undertake no obligation to publicly update any forward-looking statements. Today's press release summarizing Xenon's first quarter 2022 financial results and the accompanying quarterly report on Form 10-Q will be made available under the Investors section of our website at www.xenon-pharma.com and filed with the SEC and on SEDAR.

Now I'd like to turn the call over to Ian.

Ian Mortimer

Thanks, Sherry. Good afternoon, everyone. Thanks for joining our call. Today I will provide a high-level update on our proprietary pipeline programs and then I'll turn the call over to Chris Kenney, who will provide additional color around the new developments and next steps within our XEN1101 program, including the newly initiated XEN1101 Phase 2 clinical trial in major depressive disorder or MDD. Sherry will conclude our call by providing an update on our partner programs and briefly summarizing our financial results and anticipated key milestone events ahead. Chris Von Seggern is also on the call to provide his perspective during the Q&A session.